Brian Kotzin, MD, who was serving as the Company’s strategic advisor to the rezpegaldesleukin program since April 2023, has assumed the responsibilities of interim Chief Medical Officer. From 2017 to 2023, Dr. Kotzin supported the clinical development of rezpegaldesleukin in several different capacities at the Company. Dr. Kotzin has over 40 years of expertise in immunology and has extensive development and management experience. From 2004 to 2015, Dr. Kotzin was at Amgen, where he served as Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area, directing the global development efforts for Amgen product candidates in the inflammation area. During his time at Amgen, he also served as Vice President of Medical Sciences, which encompassed early development, biomarker development, and clinical immunology.
Prior to entering the life sciences industry, Dr. Kotzin held several positions in academia, including a professor at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease. He has also held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors and is currently an elected Master of the ACR, Member and Chairperson of the NIH Immunological Sciences Study Section, Chairperson of the NIH Autoimmunity Centers of Excellence, and Member of the Board of Directors for the Federation of Clinical Immunology Societies. He has previously served on the Board of Directors of Rigel Pharmaceuticals, Inc., Vera Therapeutics, Inc., and Kyverna Therapeutics, Inc. He currently serves on the Board of Directors of Argenx SE, Biora Therapeutics, Inc., and Genascence Corporation.
Dr. Kotzin received an M.D. from Stanford University and a bachelor’s degree in mathematics from the University of Southern California. He is board certified in rheumatology and internal medicine.